Ritipenem sodium

利替培南钠

Report date: 2022/05/12 17:24:50

NME

Base Information

Drug NameRitipenem sodium

Drug Alias Name利替培南ritipenemFCE-22101

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionBacterial penicillin-binding protein inhibitors

TargetsBacterial penicillin-binding protein

Therapy Area/IndicationsHelicobacter pylori infection

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsHelicobacter pylori infection

ATC CodeN/A